Clinical trial
A Prospective Multicenter Study on the Patterns and Clinical Significance of Lymph Node Metastasis in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Combined With Immunotherapy
NCT07899775 is registered in ClinicalTrials.gov with Hainan General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Multicenter Study on the Patterns and Clinical Significance of Lymph Node Metastasis in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy Combined With Immunotherapy
- Lead sponsor
- Hainan General Hospital
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- December 31, 2029
- Enrollment
- 103 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
gastric adenocarcinoma, gastric cancer (diagnosis), stomach neoplasms
Arms
As registered; 1 arm.
-
Neoadjuvant Chemo-immunotherapy Cohort
All enrolled participants receive standard neoadjuvant SOX chemotherapy combined with a PD-1 inhibitor for at least 2 cycles, followed by gastrectomy with D2 lymphadenectomy. No control group is assigned. Participants are observed prospectively from baseline through surgery and up to 3 years postoperatively.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Station-specific lymph node metastasis positivity rate after neoadjuvant chemoimmunotherapy
The primary outcome is the station-specific lymph node metastasis positivity rate after neoadjuvant chemoimmunotherapy, assessed by station-by-station pathologic examination of gastrectomy specimens. Each dissected nodal station (No. 1-No. 16, as applicable) is evaluated separately. For each station, the positivity rate is defined as the number of evaluable participants with at least one pathologically confirmed positive lymph node at that station divided by the number of evaluable participants in whom that station was pathologically assessed. A positive node is defined as a lymph node containing viable tumor cells on hematoxylin and eosin staining. Pathologic assessment is performed blinded to preoperative imaging, iRECIST response, and clinical treatment information. The outcome is assessed at postoperative pathology after D2 gastrectomy.
Similar trials
Same condition (Disease) and phase, most recent start first.
+1,165 more trials See the condition page